Impact of Treatment on Chagas Disease Serology
Author Information
Author(s): Viotti Rodolfo, Vigliano Carlos, Álvarez María Gabriela, Lococo Bruno, Petti Marcos, Bertocchi Graciela, Armenti Alejandro, De Rissio Ana María, Cooley Gretchen, Tarleton Rick, Laucella Susana
Primary Institution: Hospital Eva Perón, Buenos Aires, Argentina
Hypothesis
Can treatment with benznidazole effectively reduce antibody levels in chronic Chagas disease patients?
Conclusion
Benznidazole treatment significantly impacts serology in chronic Chagas disease, showing reductions in antibody levels and seronegative conversions in a shorter follow-up period than previously thought.
Supporting Evidence
- 64% of treated patients showed a decrease in antibody titers compared to 21% of untreated patients.
- 40% of treated patients achieved seronegative conversion compared to 7% of untreated patients.
- The median follow-up period to detect a decline in antibody levels was 27 months for treated patients.
Takeaway
This study shows that treating Chagas disease with a medicine called benznidazole can help lower the amount of bad germs in the body faster than we used to think.
Methodology
The study measured changes in antibody levels in 53 treated and 89 untreated patients over a median follow-up of 36 months.
Potential Biases
Potential bias due to the non-randomized nature of the study.
Limitations
The study's non-randomized design may limit the strength of the findings.
Participant Demographics
142 patients, 85 female and 57 male, mean age 42.2 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website